Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 17;98(4):e407–e415. doi: 10.1111/aos.14297

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Scatter plots demonstrating the correlation between inflammatory markers at baseline and week 2 (visit 3) for ranibizumab (blue) and the dexamethasone implant (red), respectively. First line left: IL‐6 (interleukin‐6) levels baseline compared with week 2; first line middle: IL‐8 (interleukin 8); first line right: MCP‐1 (monocyte chemo‐attractant protein 1); second line left: MMP‐9 (matrix metallopeptidase 9); second line middle: MIG/CXCL9 (monokine induced by gamma interferon); second line right: PAI‐1 (plasminogen activator inhibitor‐1); third line left: PDGF (platelet‐derived growth factor); third line middle: PIGF (placental growth factor); third line right: VEGF (vascular endothelial growth factor); fourth line left: sICAM‐1 (soluble intercellular adhesion molecule 1); fourth line middle: sVCAM (soluble vascular cell adhesion protein); fourth line right: TGFb1 (transforming growth factor beta 1); fifth line left: TGFb2 (transforming growth factor beta 2); and fifth line middle: TGFb3 (transforming growth factor beta 3).